Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The ACA and the Future of the BPCIA (<i>The Center for Biosimilars</i>)

main

08_09 Press Post_The ACA and the Future of BPCIA

Press Post: The ACA and the Future of the BPCIA (The Center for Biosimilars)

The ACA and the Future of the BPCIA (The Center for Biosimilars)

Related Content

Formycon and OneSource Specialty Pharma Partner to Manufacture Biosimilars

Teva and Samsung Bioepis Enter Into Commercialization Agreement for OPUVIZ in Canada

Caremark Settles PBM FTC Action Regarding Reimbursement Practices, Second Major PBM to Settle

Royalty Reductions Are Becoming More Expansive

Accord BioPharma Announces FDA Approval of Pegfilgrastim Biosimilar

Teva and Polpharma Biologics Announce Global Licensing Agreement for Ocrelizumab Biosimilar for Multiple Sclerosis

Antitrust & Competition Life Sciences 1H 2026 Update

Harrow Re-Launches BYOOVIZ (ranibizumab-nuna) in the United States

Goodwin Advised Freenome in Business Combination With Perceptive Capital Solutions Corp. and $310 Million Financing

Goodwin Advises Repligen in Acquisition of BioLife Solutions for Approximately $1.5 Billion

Goodwin Advises Hansoh Pharma on Intellectual Property Aspects for License Collaboration and Strategic Investment With Avere for $120 Million Upfront and Up to $2.18 Billion in Milestone Payments

Goodwin Guides IP for Pharmakon on Up to $200 Million Financing for Kestra Medical Technologies

Goodwin Advises LFPI on Its Majority Investment in I-Run

Goodwin Advises Bpifrance and Andera Partners on the €33 Million Series C Financing of Cyllene Therapeutics

Goodwin Secures Two Appellate Victories in High-Stakes Life Sciences Disputes

Goodwin Expands Southern California Life Sciences Platform with Industry Expert Matt Bresnahan as Co-Chair of San Diego Office

Life Sciences

Life Sciences Patent Prosecution & Counseling

Patent Litigation

Patent Prosecution & Counseling

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation